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A proportion of Alzheimer’s disease cases displays inclusions of the RNA-binding protein, TDP-43.
Considering the pathogenic role of tau mis-splicing, we compared tau isoform expression between
Alzheimer’s disease cases with or without TDP-43 inclusions. The average ratio of tau isoforms con-
taining or lacking exon 10 (4R/3R ratio) or the total level of tau mRNA was not signiﬁcantly
different between cases with or without TDP-43 pathology in any of the brain regions examined.
Although TDP-43 functions may be affected, TDP-43 does not critically regulate expression or splicing of
tau in Alzheimer’s disease suggesting that TDP-43 contributes to Alzheimer’s disease through mecha-
nisms independent of tau.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Alzheimer’s disease (AD) is characterized by Ab and tau pa-
thologies in affected brain areas. In addition, 20%e30% of AD cases
display cytoplasmic inclusions of transactive response DNA-binding
protein of 43 kDa (TDP-43). The presence of TDP-43 inclusions in
the hippocampus and entorhinal cortex correlates with neuronal
loss in late onset dementia and, furthermore, a strong correlation
exists between the presence of TDP-43 pathology and speciﬁc
clinical features of AD, especially impaired cognition and amnesia
(Davidson et al., 2011). TDP-43 is a predominantly nuclear protein
that regulates RNA splicing and stability of multiple targets;
therefore, mislocalization and aggregation of TDP-43 couldand Clinical Neuroscience,
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Inc. This is an open access articlecontribute to pathogenesis in a subgroup of AD cases by affecting
directly or indirectly the level of expression or splicing of speciﬁc
targets. As mis-splicing of tau exon 10 (E10) can be pathogenic
(Niblock and Gallo, 2012), we compared tau expression and splicing
in affected brain regions in AD patients with or without TDP-43
pathology to establish a possible contribution of abnormal TDP-
43 activity in AD through tau splicing.2. Methods
Frozen brain tissue was obtained from individuals free from
neurological disease and individuals with AD and controls. Cases
were assessed for TDP-43 pathology by immunocytochemistry.
RNA was extracted using the Qiagen RNeasy/lipid kit (Qiagen). Tau
E10 splicing was analyzed by end-point reverse transcription po-
lymerase chain reaction using a forward primer 50-labelled with an
infrared ﬂuorescent dye, yielding a signal independent of the length
of the individual products. Gels were imaged, and polymerase chain
reaction products were quantiﬁed using an Odyssey Infrared Im-
aging System (LI-COR Biosciences) (Supplementary Fig. 2A). Sta-
tistical analysis was carried out using one-way ANOVA and Student
t test.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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We analyzed tau splicing in a cohort of 14 AD cases with
(ADTDPþ) and 15 AD cases without (ADTDP) TDP-43 inclusions
and 15 age-matched nondemented healthy controls
(Supplementary Table 1). The amygdala is consistently affected by
tau pathology in AD and, in cases with TDP-43 pathology, the
amygdala consistently contains TDP-43 inclusions. In the amygdala,
the averagemolar ratio of isoforms containing or lacking E10 (4R/3R
ratio) ranged between 0.7 and 1.2 in control cases. Individually, the
ADTDPþ and ADTDP groups showed a borderline signiﬁcant in-
crease in the 4R/3R ratio compared to controls (Supplementary
Fig. 2B). However, the average 4R/3R ratios were not signiﬁcantly
different between the ADTDPþ and ADTDP groups.
4. Discussion
Mutations in the TARDBP gene, encoding TDP-43, have been
linked to familial forms of amyotrophic lateral sclerosis (Sreedharan
et al., 2008), thus arguing for a pathogenic role of TDP-43. Tau pre-
mRNA has not been found to be a direct target of TDP-43 (Tollervey
et al., 2011). However, TDP-43 is part of an RNA regulatory complex
that includes fused in sarcoma (FUS). FUS binds to tau pre-mRNA,
and FUS downregulation promotes E10 inclusion in tau mRNA in
rodents (Orozco et al., 2012). Whether tau mis-splicing contributes
to sporadic AD has been a matter of debate (Niblock and Gallo,
2012). Considering the pathological importance of tau splicing
and the role of TDP-43 as a splicing regulator, it was important to
determine whether a correlation existed between the presence of
TDP-43 pathology in sporadic AD cases and the 4R/3R ratio in
affected brain areas. Levels of E10 inclusion were not signiﬁcantly
different between AD cases with or without TDP-43 pathology;
however, we found a borderline signiﬁcant increase in 4R tau in the
combined AD cases compared to controls. The results could have
been confounded by parameters inherent to the use of postmortem
diseased brain tissue such as changes in cell population resulting
from cell loss and gliosis. In the present study, we compared indi-
vidual transcripts between 2 disease subgroups that would have a
similar extent of cell population change and, in addition, we found
no difference in tau mRNA levels between AD and control cases
which reﬂects the quality of the material selected. In conclusion,
although TDP-43 RNA regulatory functions may be affected in a
subgroup of Alzheimer’s disease cases, TDP-43 does not critically
regulate expression or splicing of tau suggesting that TDP-43 con-
tributes to clinical features of Alzheimer’s disease through mecha-
nisms independent of tau. Considering the role of TDP-43 as aregulator of RNA processing and its importance in dementia, large
scale genome-wide studies are required to determine the signiﬁ-
cance of TDP-43 pathology in Alzheimer’s disease.
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Appendix A. Supplementary data
Supplementary data related to this article can be found at the
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